Trial results

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

NCT06282458 on ClinicalTrials.gov · last registry update 2025-09-17

Finished 11 April 2025, after enrolling 168 people. Primary outcome, as filed: The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Veru Inc.

Sponsor type

Industry

Enrollment

168

Started

2024-04-29

Primary completion

2025-04-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.

Conditions studied

Muscle Loss · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.